Trapped Between Full Capacity and Commodity Pricing
Q1 delivered revenue growth of 4.9% but PAT collapsed 27.3% quarter-on-quarter. Management's feed-cost headwind was worse than prior guidance implied, with 2-3 months of margin pressure ahead and zero room for volume growth.
On the headline, SKM's Q1 FY-2027 tells a story of modest resilience: revenue up 4.9% year-on-year to ₹184.3 crore, PAT up 46.5% to ₹23.8 crore. Then you look at the quarter-on-quarter numbers and the real story emerges—revenue flat (-1.3%) and PAT down 27.3%—and you realize the company is not in growth mode. It is in a margin trap, squeezed between full capacity utilization and commodity pricing with no way out for the next 2-3 quarters.
The Tension: Growth Stalled, Margins Crashing
₹184.3 Cr
+4.9% | on prior guidance
-1.3%
Full capacity = demand ceiling hit
+46.5%
Low prior base; misleading
-27.3%
Margin collapse from soya costs
The year-on-year gains are misleading. PAT jumped 46.5% but off a depressed prior quarter—the real signal is the 27.3% quarter-on-quarter collapse, driven by soya cost inflation that management now admits will persist for 2-3 months minimum. Net profit margin compressed to 12.4% (down from ~16% implied prior), operating margin to 16.9%, and neither has any near-term relief mechanism. Management made explicit on the call: they have zero cost-pass mechanism with customers ('pricing is not dependent on our cost…it is driven by market prices'). The realization improvement to ₹770/kg—up ₹48 versus ₹722 prior—came entirely from rupee depreciation, not pricing power or operational excellence.
Management's Claims vs. What Holds Up
Full capacity utilization; modest growth FY27
Revenue +4.9% YoY, -1.3% QoQ on stated full capacity
Supported
Feed cost is biggest margin pressure; 2-3 months minimum headwind
PAT -27.3% QoQ, NPM 12.4%; no month-by-month roadmap provided
Supported, magnitude vague
Realization improved to ₹770/kg
Improvement credited to 'primarily exchange rate (₹ depreciation)', not pricing or volume mix
Partially overstated
No pricing power; prices market-driven, cost cannot be passed
MD: 'any increase in cost cannot be transferred…pricing not dependent on our cost'
Supported; structural weakness
Easy sheds (5% cost reduction) online by Nov-Dec 2026
4 complete; rest by Nov-Dec 2026 (4 months away, aggressive timeline)
On track but execution-dependent
What Changed This Quarter
Feed cost inflation materialized worse than prior guidance; soya 'substantial increase'
Capacity constraint confirmed real (not transient); QoQ revenue flat on full utilization
Japan office approval delayed Jun-Jul → Aug-Sep 2026; no new customers won yet
Branded eggs (SKM Best acquisition) active; ₹40-50 Cr revenue added this FY
Branded EBITDA margins explicitly lower than core egg powder business
How the Street Is Positioned
The stock opened at ₹273.5 on result day (Jul 29) and fell 8.63% on the day-1 reaction—a sharp repricing that the market read as justified. The selloff reflects belief that the margin collapse from feed costs was worse than prior guidance had signaled, the relief timeline (2-3 months) is vague, and the company has confirmed it has zero pricing power to recover costs.
₹249.85
Day 1 down -8.63%
₹371.6
-32.76% drawdown
₹143.1–₹371.6
+74.6% off low
10.3
Oversold, but not a buy signal
The stock is well below its 20-day and 50-day moving averages but above the 200-day, limiting technical support. More telling: FII ownership has collapsed to 0.49% (down 0.27pp QoQ from 0.76%), while DII ownership remains minimal at 0.36%. Bulk deals show some nibbling at ₹231–₹232 (NK Securities, Alphagrep, Junomoneta rotating in), but earlier selling at ₹190–₹199 (SILVERLEAF, BACHA GOUTHAM) suggests institutional rotation out, not conviction. The thin institutional ownership and post-result selling confirm that the margin deterioration is being treated as genuine, not a one-quarter blip.
The Bull Case vs. The Bear Case
Ranked Risks (by how much they should concern a holder)
Feed cost inflation (soya, uncontrollable) extends beyond 2-3 months
HighZero cost-pass mechanism with customers. Any extension of soya costs will keep PAT depressed. Q1 already showed -27.3% QoQ damage; Q2 will test whether the relief timeline holds.
Zero pricing power in international commodity markets
HighManagement explicitly: cannot transfer costs to buyers. Growth must come from volume (capex, FY28+) or market price recovery (uncontrollable). Structural vulnerability.
Capacity fully utilized; zero volume growth until capex (FY28+)
HighQoQ revenue -1.3% despite full capacity confirms demand ceiling hit. No volume upside for 18+ months. Growth must be price-led, but international prices are 'quite stable' (management's words).
Execution delays on easy sheds and capex timeline
MediumEasy sheds Nov-Dec 2026 completion is 4 months away (aggressive). Japan office already delayed Jun-Jul → Aug-Sep. Biogas still in test/commercialization phase (Sept 2026 target unproven).
Branded eggs margin dilution
MediumSKM Best acquisition adds ₹40-50 Cr revenue but at lower EBITDA margins than core egg powder. Revenue grows; PAT per rupee of revenue declines. Margin recovery deferred to FY28+.
What to Watch Next
1 · Q2 QoQ PAT (September 2026 result)
The litmus test for feed cost relief. Management says 2-3 months minimum headwind. If Q2 PAT remains down >15% QoQ, the relief timeline is slipping. If it improves ≥10% QoQ, margin recovery thesis holds. This single number makes or breaks confidence in guidance.
2 · Easy sheds full completion and 5% cost reduction realized (Nov-Dec 2026)
Management committed to 5% overall production cost savings once all sheds are online. Q4 results will show whether that translates to 50-80 bps OPM recovery. If delayed or underwhelming, capex and execution credibility take a hit.
3 · Capex board approval and branded business plan (Oct 2026–Mar 2027)
₹400 Cr capex board approval by October; branded eggs business plan finalized by March 2027. These reset the multi-year narrative. However, without Q2-Q3 margin recovery, the market is unlikely to re-rate on forward expectations.
The Single Number to Track
From Q2 FY-2027 onwards, watch quarterly PAT sequentially. The margin compression in Q1 (-27.3% QoQ) was attributed to feed costs with a stated 2-3 month relief window. If Q2 QoQ PAT improves, the thesis holds and you can look past near-term pain to the capex story. If Q2 PAT stays flat or worsens, the feed cost timeline is slipping and the margin trap deepens. EPS will follow, but the PAT trend is the earliest signal of whether guidance is tracking.
SKM is not a broken story, but it is a trapped one. Full capacity, commodity pricing, and zero pricing power create a structural squeeze for the next 2-3 quarters. The ₹400 crore capex plan and branded eggs diversification are credible long-term bets, but they arrive in FY28-29 at the earliest. The margin profile of the latter is dilutive near-term. Management is pragmatic and transparent about these constraints (they don't hide the 'no cost-pass' reality), but transparency doesn't change the math.
The day-1 selloff of 8.63% was justified. The oversold RSI of 10.3 hints at reversal opportunity only if catalysts (easy sheds, feed cost relief, capex approval) deliver on schedule in the months ahead. Until then, the stock is a hold-and-watch, not a buy-the-dip. The narrative shifts when Q2 PAT trends north; until it does, the trap remains real.
Full capacity, flat growth, feed-cost margin trap
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Guided for 'modest FY27 growth'—quarter is delivering modest (+4.9%), matching expectation. However, QoQ margin deterioration (-27.3% PAT) exceeded any disclosed headwind magnitude. Feed cost relief timelines vague.
Cautiously Optimistic
next 1–2 quarters
Cautiously Optimistic
multi-year
Company is trapped between full capacity (no volume growth) and commodity pricing (no pricing power) in near term, with feed-cost headwinds depressing margins for 2-3 months. Multi-year capex plan (₹400 Cr, FY28-29) is credible but too distant. Delivered Q1 shows +4.9% revenue but -27.3% QoQ PAT—margin compression is real, not transient.
₹184.3 Cr
Revenue · +4.9% YoY₹23.8 Cr
Reported PAT · +46.5% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
Full capacity utilization; modest growth expected in FY27
METRevenue +4.9% YoY, -1.3% QoQ; PAT flat YoY on reported but -27.3% QoQ
Feed cost is biggest margin pressure; 2-3 months more headwind
METNPM 12.4% (vs ~16% implied prior), OPM 16.9%; PAT down 27.3% QoQ attributed to soy/feed
Realization improved to ₹770/kg (vs ₹722 prior)
METRealization stated as ₹770; management credits primarily exchange rate (₹ depreciation)
No pricing power internationally; prices market-driven, not cost-plus
METManagement explicitly: 'not B2C2B...cannot transfer cost to customer...pricing not dependent on cost'
Capacity fully utilized; no room for volume growth rest of FY27
METDelivered -1.3% QoQ revenue decline on stated full capacity; future growth price-led only
Earnings quality
What changed since the last call
Feed cost inflation materialized
DowngradeSoya 'substantial increase'; margin compression -27.3% QoQ not fully offset by realization gains. Management now says 2-3 month persistence vs prior vague outlook.
Capacity constraint confirmed
NeutralFull utilization stated; revenue -1.3% QoQ on full capacity signals demand ceiling, not growth (prior guidance said 'modest' for FY27—being met, but narrower runway than implied).
Branded eggs strategy active
NewSKM Best Eggs acquisition completed; ₹40-50 Cr revenue expected THIS FY (but margins deferred to next FY, admittedly LOWER than egg powder core business).
Japan office delayed
DowngradeExpected approval postponed Jun-Jul to Aug-Sep 2026; already have contracts without branch (limited incremental customer win so far).
The Q&A
Analysts pressed hard on margin compression (Mervan, Saurabh) and pricing power—management conceded no cost-pass mechanism, openly admitted 'I don't know how market behaves'. On capex ROI, Pramukh challenged sustainability investment; management deflected to 'necessary for E-market'. Tone: defensive but honest, not evasive.
Margin compression drivers — Mervan Kotwal
AnsweredTwo factors: feed cost increase is biggest; soya substantial. Shell rate no longer impact (own production). Will take 2-3 months minimum to abate.
Pricing power, cost pass-through — Saurabh Dhole
AnsweredNo. We sell, they don't ask. Cost cannot be transferred; driven by market price and competition. Pricing not dependent on our cost.
Volume growth outlook — Rajesh
PartialNo room to increase volume (capacity constraint). Bottom line influenced by international price and feed cost. Prices stable; maybe improvement in 2-3/4 for egg white.
Branded eggs ROI vs core — Saurabh Dhole
PartialHistorically not our operation. Margins will be slower but volume scale easier. Growth potential in India much higher than powder market. Strategic for long-term revenue balance.
Easy sheds cost advantage — Sam
Answered5% overall production cost reduction (productivity + consistency + feed conservation). First 4 done; rest by Nov-Dec 2026.
Japan office expansion — Sam
AnsweredApproval postponed 1-2 months (was Jun-Jul, now Aug-Sep). Already have contracts without branch. One new opportunistic customer; branch impact not yet increased.
Russia exports stability — Sam
Answered~150 tons/month. War 'long over', not impacting now. Had Iran war delivery issues last FY (airshipped 6-7 containers). Now normal; working on 2nd distributor for Q3-Q4.
Export mix & realization — Gopal
AnsweredNo. 6-7 containers on sea delayed (Russia logistics); had to airship replacement, reducing utilization. Will redeploy in Jul-Aug. Not strategic withholding.
Capex timing & guidance — Hiten Boricha
DodgedDetails to follow offline. ₹400 Cr is egg production capacity expansion (supply for branded). Brand plan by Mar 2027. Investments will be known by end of March.
Long-term pricing strategy — Rajas
PartialCannot guarantee. Effort to increase top line continuously. Strategic goals 2030, 2035. Market behavior unpredictable; 'I even myself don't understand how it moves.'
Guidance
FY27 modest growth; full capex capacity constraint
HighOn track (+4.9% YoY Q1). No new revenue targets set; maintaining prior '2030 ₹1000 Cr' aspiration but vague.
Feed cost pressure to persist 2-3 months minimum
HighSoya inflation unmitigated; no cost-pass mechanism with customers. Margin recovery depends on market prices, not internal action.
₹400 Cr capex for layer bird capacity (40 lakh birds by 2029); board approval by Oct 2026
MediumPhased FY28-29. Easy sheds (20 lakh birds) on track Nov-Dec 2026. Branded eggs investment separate, plan by Mar 2027.
Branded eggs: ₹40-50 Cr revenue THIS year (already acquired SKM Best); margin growth deferred to next FY
MediumFull-year estimate; margin profile TBD. Strategy is dilutive near-term (lower margins than powder).
Risks the call surfaced
Feed cost inflation
HighSoya costs 'substantial increase'; management admits zero cost-pass to customers. Expected 2-3 month persistence minimum. Margin compression -27.3% QoQ documented.
Pricing power absence
HighInternational B2C2B market; management explicitly states: 'any increase in cost cannot be transferred to customer, but it is driven by...market prices...our pricing is not dependent on our cost.' Zero negotiating leverage.
Capacity constraint
HighFull capacity utilization; revenue -1.3% QoQ despite full utilization signals ceiling. No volume headroom. All near-term growth must be price-led, but international prices 'quite stable' (management's words).
Execution risk (capex & strategy)
MediumEasy sheds (Nov-Dec 2026 completion) is 4 months away (aggressive). Japan office delayed Jun-Jul → Aug-Sep. Branded eggs margins lower than core (admitted by MD). Biogas commercialization unproven (test marketing now, commercial Sept).
Branded eggs margin dilution
MediumSKM Best Eggs acquisition adds ₹40-50 Cr revenue THIS year, but EBITDA margins explicitly admitted to be 'slower' than egg powder core. Margin development deferred to next FY. Risk: revenue grows but NPM compressed.
Management
Score 6/10. Transparent on weaknesses (margin compression, no pricing power, full capacity); hedged on specifics (sends details offline). Not evasive but cautious. Admits uncertainties ('don't understand how market behaves'). Prior FY26 ₹767 Cr revenue achieved (58% YoY growth ✓). CAPEX plan on track (easy sheds 50% done). Japan office delayed Jun-Jul → Aug-Sep (miss). Biogas commercial still in test phase (slower rollout).
1 · Oct-Nov 2026
Board approval of capex expansion plan (₹400 Cr for 40L birds)
2 · Sep 2026
Biogas/organic fertilizer commercial launch (test marketing now)
3 · Mar 2027
Branded eggs business plan finalized; rollout in 5 locations planned
Delivered Q1 shows +4.9% revenue but -27.3% QoQ PAT—margin compression is real, not transient.
SKM Egg Q1 FY27: consolidated PAT +46% YoY on margin gains, revenue growth stays modest
PAT +46.4% YoY · revenue +4.87% · margins expanding
₹184.26 Cr
+4.87% YoY
₹23.82 Cr
+46.4% YoY
12.43%
+3.4pp YoY
₹4.53
SKM Egg Products' consolidated Q1 FY27 print shows profit outrunning revenue: PAT for the period came in at ₹23.82 Cr, up 46.4% YoY, while revenue from operations grew a modest 4.87% YoY to ₹184.26 Cr. No exceptional items were recorded in either period, so the YoY jump is a clean operating/other-income story, not a one-off. Sequentially both revenue (-1.3%) and PAT (-27.3%) fell from a seasonally strong Q4 FY26 (₹186.65 Cr revenue, ₹32.78 Cr PAT) — a normalization off a high base rather than a red flag.
Q1 FY-2027 vs prior quarters
The margin bridge is the real driver of the YoY beat: consolidated net margin expanded to ~12.9% from ~9% a year ago, aided by cost of material consumed falling 5.6% YoY (₹108.46 Cr vs ₹114.93 Cr) even as revenue rose, plus other income up 70% YoY (₹7.32 Cr vs ₹4.30 Cr). Management's own results slide (standalone basis) frames the quarter the same way: sales +3% YoY, operating profit +33% YoY, PBT +46% YoY — a margin-led, not volume-led, print. The QoQ margin compression (from ~17.9% NPM in Q4 to ~12.9% now) reflects a genuine step-down in the core business rather than an other-income base effect, since Q4's other income was actually negative (-₹3.35 Cr, a mark-to-market loss) yet still delivered a higher PBT.
The stock went into the print at ₹275, down 6.1% over the past month of trading.
What the summary numbers don't show
Consolidated basic EPS ₹4.53 vs ₹3.09 YoY and ₹6.21 in Q4 FY26
Management reported stellar financial results for FY25-26, with revenue up 58% YoY to ₹767 crores and PAT crossing ₹100 crores for the first time. Looking ahead, the company has a significant CAPEX plan of ₹400 crores for expanding layer bird capacity to 40 lakh birds by 2029, aimed at improving bottom-line efficiency
— This quarter: met
Sub-5% YoY revenue growth is consistent with management's own FY27 outlook from the May 2026 concall, which flagged modest near-term topline growth given the plant is running at full capacity, with the ₹400 Cr capex plan to expand layer-bird capacity to 40 lakh birds by 2029 aimed at bottom-line efficiency rather than immediate revenue growth — this quarter's soft-revenue/strong-profit shape tracks that framing (guidance: met). No consensus estimates specific to this quarter's revenue or PAT turned up in public sources, so vsStreet is unknown rather than assumed. Alongside the results, the board recommended a final FY25-26 dividend of ₹1.25/share (25% of ₹5 face value), and the quarter also carried a Chairman Emeritus appointment and CMD transition (24 June 2026) — a governance change that doesn't touch the P&L but is worth tracking going forward.
W1
FY27 topline trajectory against management's own 'modest growth' guidance and progress on shell-egg export/domestic market expansion focus
W2
Ramp of the ₹400 Cr capex plan to expand layer-bird capacity to 40 lakh birds by 2029, aimed at bottom-line efficiency
W3
Margin sustainability given other income rose 70% YoY to ₹7.32 Cr — watch whether core operating margin (ex-other income) holds without this tailwind
Both statements reconcile exactly (Total Income = Revenue+Other Income; PAT = PBT-tax); no exceptional items in either period. Consolidated PAT (23.82 Cr) is split ₹23.85 Cr owners / -₹0.03 Cr minority. Unreviewed subsidiary SKM Europe BV posted a ₹0.16 Cr net loss for the quarter, flagged immaterial by auditors. Our database's year-ago EPS (₹6.18) does not match this filing's Q1 FY26 basic EPS column (₹3.09) — appears to be a TTM/annualised EPS in our records vs this filing's non-annualised quarterly EPS, not a restatement error.